Abstract
Avdoralimab (IPH5401) is a monoclonal antibody that inhibits the binding of the complement factor C5a to the receptor C5aR1. Preclinical analysis revealed that inhibition of C5a/C5aR1 axis limited myeloid derived suppressor cells (MDSCs) and increased CD8 T-cell tumor infiltration, promoting tumor reduction and limiting metastatic potential. Furthermore, the combined use of C5a/C5aR1 inhibition and anti-PD(L)1 therapy (IO) was shown to be superior to each modality alone in terms of reducing tumor volume and improving survival in several preclinical murine models.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.